Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Sufenta Inj 50mcg/ml	Liquid	50 mcg	Intravenous	Janssen Pharmaceutica, Division Of Janssen Ortho Inc.	1985-12-31	1996-09-10
Sufenta Inj 50mcg/ml	Liquid	50 mcg	Epidural; Intravenous	Janssen Pharmaceuticals	1985-12-31	2007-11-26
Sufentanil Citrate	Injection	50 ug/mL	Epidural; Intravenous	Akorn	2010-12-01	Not applicable
Sufentanil Citrate Injection USP	Solution	50 mcg	Epidural; Intravenous	Sandoz Canada Incorporated	2001-08-01	Not applicable
Sufentanil Citrate Injection, USP	Solution	50 mcg	Epidural; Intravenous	Sterimax Inc	2016-10-18	Not applicable
Zalviso	Tablet	15 μg	Sublingual	Grunenthal Gmb H	2015-09-18	Not applicable
Zalviso	Tablet	15 μg	Sublingual	Grunenthal Gmb H	2015-09-18	Not applicable
Zalviso	Tablet	15 μg	Sublingual	Grunenthal Gmb H	2015-09-18	Not applicable
Zalviso	Tablet	15 μg	Sublingual	Grunenthal Gmb H	2015-09-18	Not applicable
Zalviso	Tablet	15 μg	Sublingual	Grunenthal Gmb H	2015-09-18	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Sufentanil Citrate	Injection, solution	50 ug/mL	Epidural; Intravenous	Hospira, Inc.	1996-12-11	2018-05-18
Sufentanil Citrate	Injection	.05 mg/mL	Epidural; Intravenous	West Ward Pharmaceutical	1995-12-15	Not applicable
Sufentanil Citrate	Injection	.05 mg/mL	Epidural; Intravenous	West Ward Pharmaceutical	1995-12-15	Not applicable
Sufentanil Citrate	Injection, solution	50 ug/mL	Epidural; Intravenous	Hospira, Inc.	1996-12-11	Not applicable
Sufentanil Citrate	Injection	.05 mg/mL	Epidural; Intravenous	West Ward Pharmaceutical	1995-12-15	Not applicable

International/Other Brands

Chronogesic (DURECT) / Disufen (Angenerico) / Fastfen (Cristália) / Sufenta (Janssen) / Sufenta Forte (Janssen) / Sufenta mite (Janssen) / Sufentil (Claris Lifesciences Ltd.) / Zuftil (Pisa)

Categories

UNII

AFE2YW0IIZ

CAS number

56030-54-7

Weight

Average: 386.551
Monoisotopic: 386.202798904

Chemical Formula

C₂₂H₃₀N₂O₂S

InChI Key

GGCSSNBKKAUURC-UHFFFAOYSA-N

InChI

InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3

IUPAC Name

N-[4-(methoxymethyl)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide

SMILES

CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1

Pharmacology

Indication

Used as an analgesic adjunct in anesthesia and as a primary anesthetic drug in procedures requiring assisted ventilation and in the relief of pain.

Associated Therapies

Pharmacodynamics

Sufentanil is a synthetic opioid analgesic. Sufentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Sufentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Sufentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.

Mechanism of action

Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Sufentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids open calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

Target	Actions	Organism
AMu-type opioid receptor	agonist	Human
UDelta-type opioid receptor	agonist	Human
UKappa-type opioid receptor	other	Human

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

265 minutes

Clearance

Not Available

Toxicity

LD₅₀: 18.7 mg/kg (IV in mice)

Affected organisms

Humans and other mammals

Pathways

Pathway	Category
Sufentanil Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2,5-Dimethoxy-4-ethylamphetamine	2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Sufentanil.	Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine	2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Sufentanil.	Experimental
3,4-Methylenedioxyamphetamine	3,4-Methylenedioxyamphetamine may increase the analgesic activities of Sufentanil.	Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine	4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Sufentanil.	Experimental, Illicit
7-Nitroindazole	The risk or severity of adverse effects can be increased when Sufentanil is combined with 7-Nitroindazole.	Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Sufentanil.	Experimental
Acebutolol	Sufentanil may increase the bradycardic activities of Acebutolol.	Approved, Investigational
Acepromazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Aceprometazine.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Acetazolamide.	Approved, Vet Approved
Acetyl sulfisoxazole	The metabolism of Sufentanil can be decreased when combined with Acetyl sulfisoxazole.	Approved, Vet Approved
Aclidinium	The risk or severity of adverse effects can be increased when Aclidinium is combined with Sufentanil.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Sufentanil is combined with Adipiplon.	Investigational
Agmatine	The risk or severity of adverse effects can be increased when Agmatine is combined with Sufentanil.	Experimental, Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Agomelatine.	Approved, Investigational
Alaproclate	Sufentanil may increase the serotonergic activities of Alaproclate.	Experimental
Alcuronium	The risk or severity of adverse effects can be increased when Alcuronium is combined with Sufentanil.	Experimental
Aldesleukin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Aldesleukin.	Approved
Alfaxalone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Alfentanil.	Approved, Illicit
Alimemazine	Alimemazine may increase the hypotensive activities of Sufentanil.	Approved, Vet Approved
Aliskiren	The risk or severity of adverse effects can be increased when Sufentanil is combined with Aliskiren.	Approved, Investigational
Allopregnanolone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Allopregnanolone.	Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Alphacetylmethadol.	Experimental, Illicit
Alphaprodine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Alphaprodine.	Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Sufentanil.	Approved, Illicit, Investigational
Alprenolol	Sufentanil may increase the bradycardic activities of Alprenolol.	Approved, Withdrawn
Alvimopan	The risk or severity of adverse effects can be increased when Sufentanil is combined with Alvimopan.	Approved, Investigational
Amifostine	The risk or severity of adverse effects can be increased when Amifostine is combined with Sufentanil.	Approved, Investigational
Amikacin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amikacin.	Approved, Investigational, Vet Approved
Amiloride	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amiloride.	Approved
Amiodarone	The risk or severity of adverse effects can be increased when Amiodarone is combined with Sufentanil.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amitriptyline.	Approved
Amlodipine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amlodipine.	Approved
Ammonium chloride	Ammonium chloride may increase the excretion rate of Sufentanil which could result in a lower serum level and potentially a reduction in efficacy.	Approved, Investigational, Vet Approved
Amobarbital	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amobarbital.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amoxapine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amperozide.	Experimental
Amphetamine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amphetamine.	Approved, Illicit, Investigational
Amyl Nitrite	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amyl Nitrite.	Approved
Anisotropine Methylbromide	The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Sufentanil.	Approved
Apalutamide	The serum concentration of Sufentanil can be decreased when it is combined with Apalutamide.	Approved, Investigational
Apomorphine	The risk or severity of adverse effects can be increased when Apomorphine is combined with Sufentanil.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Apraclonidine.	Approved
Aprepitant	The serum concentration of Sufentanil can be increased when it is combined with Aprepitant.	Approved, Investigational
Aripiprazole	Aripiprazole may increase the hypotensive activities of Sufentanil.	Approved, Investigational
Arotinolol	The risk or severity of adverse effects can be increased when Arotinolol is combined with Sufentanil.	Investigational
Arsenic trioxide	The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sufentanil.	Approved, Investigational
Articaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Articaine.	Approved
Asenapine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Asenapine.	Approved
Atazanavir	The metabolism of Sufentanil can be decreased when combined with Atazanavir.	Approved, Investigational
Atenolol	Sufentanil may increase the bradycardic activities of Atenolol.	Approved
Atomoxetine	The metabolism of Sufentanil can be decreased when combined with Atomoxetine.	Approved
Atracurium	The risk or severity of adverse effects can be increased when Atracurium is combined with Sufentanil.	Approved, Experimental, Investigational
Atracurium besylate	The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Sufentanil.	Approved
Atropine	The risk or severity of adverse effects can be increased when Atropine is combined with Sufentanil.	Approved, Vet Approved
Azaperone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Azaperone.	Investigational, Vet Approved
Azelastine	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Azilsartan medoxomil.	Approved, Investigational
Azosemide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Azosemide.	Investigational
Baclofen	The risk or severity of adverse effects can be increased when Sufentanil is combined with Baclofen.	Approved
Barbexaclone	Barbexaclone may increase the hypotensive activities of Sufentanil.	Experimental
Barbital	The risk or severity of adverse effects can be increased when Sufentanil is combined with Barbital.	Illicit
Barnidipine	The risk or severity of adverse effects can be increased when Barnidipine is combined with Sufentanil.	Approved
Befunolol	Sufentanil may increase the bradycardic activities of Befunolol.	Experimental
Benactyzine	The risk or severity of adverse effects can be increased when Benactyzine is combined with Sufentanil.	Withdrawn
Benazepril	The risk or severity of adverse effects can be increased when Sufentanil is combined with Benazepril.	Approved, Investigational
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Bendroflumethiazide.	Approved
Benmoxin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Benmoxin.	Withdrawn
Benperidol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Benperidol.	Approved, Investigational
Benzatropine	The risk or severity of adverse effects can be increased when Benzatropine is combined with Sufentanil.	Approved
Benzphetamine	The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Benzphetamine.	Approved, Illicit
Benzyl alcohol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Benzyl alcohol.	Approved
Bepridil	The risk or severity of adverse effects can be increased when Bepridil is combined with Sufentanil.	Approved, Withdrawn
Beractant	Sufentanil may increase the bradycardic activities of Beractant.	Approved
Betaxolol	Sufentanil may increase the bradycardic activities of Betaxolol.	Approved, Investigational
Bevantolol	Sufentanil may increase the bradycardic activities of Bevantolol.	Approved
Biperiden	The risk or severity of adverse effects can be increased when Biperiden is combined with Sufentanil.	Approved, Investigational
Bisacodyl	The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Sufentanil.	Approved
Bisoprolol	Sufentanil may increase the bradycardic activities of Bisoprolol.	Approved
BL-1020	BL-1020 may increase the hypotensive activities of Sufentanil.	Investigational
Boceprevir	The metabolism of Sufentanil can be decreased when combined with Boceprevir.	Approved, Withdrawn
Bopindolol	Sufentanil may increase the bradycardic activities of Bopindolol.	Approved
Bornaprine	The risk or severity of adverse effects can be increased when Bornaprine is combined with Sufentanil.	Experimental
Bortezomib	The metabolism of Sufentanil can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Sufentanil can be decreased when it is combined with Bosentan.	Approved, Investigational
Bretylium	Bretylium may increase the bradycardic activities of Sufentanil.	Approved
Brexpiprazole	The risk or severity of adverse effects can be increased when Sufentanil is combined with Brexpiprazole.	Approved, Investigational
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved
Brofaromine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Brofaromine.	Experimental
Bromazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Bromazepam.	Approved, Illicit, Investigational
Bromisoval	The risk or severity of adverse effects can be increased when Sufentanil is combined with Bromisoval.	Experimental
Bromocriptine	The risk or severity of adverse effects can be increased when Bromocriptine is combined with Sufentanil.	Approved, Investigational
Bromotheophylline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Bromotheophylline.	Approved
Bromperidol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Bromperidol.	Approved, Investigational
Brompheniramine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Brotizolam.	Approved, Investigational, Withdrawn
Bucindolol	Sufentanil may increase the bradycardic activities of Bucindolol.	Investigational
Bufuralol	Sufentanil may increase the bradycardic activities of Bufuralol.	Experimental, Investigational
Bumetanide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Bumetanide.	Approved
Bupivacaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Bupivacaine.	Approved, Investigational
Bupranolol	Sufentanil may increase the bradycardic activities of Bupranolol.	Approved
Buprenorphine	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The risk or severity of adverse effects can be increased when Sufentanil is combined with Bupropion.	Approved
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Sufentanil.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Sufentanil.	Approved, Illicit
Butacaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Butacaine.	Vet Approved
Butalbital	The risk or severity of adverse effects can be increased when Sufentanil is combined with Butalbital.	Approved, Illicit
Butamben	The risk or severity of adverse effects can be increased when Sufentanil is combined with Butamben.	Approved, Withdrawn
Butethal	The risk or severity of adverse effects can be increased when Sufentanil is combined with Butethal.	Approved, Illicit
Butorphanol	Butorphanol may decrease the analgesic activities of Sufentanil.	Approved, Illicit, Vet Approved
Butylscopolamine	The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Sufentanil.	Approved, Investigational, Vet Approved
Calfactant	Sufentanil may increase the bradycardic activities of Calfactant.	Approved
Canagliflozin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Canagliflozin.	Approved
Candesartan cilexetil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Candesartan cilexetil.	Approved
Canertinib	The risk or severity of adverse effects can be increased when Sufentanil is combined with Canertinib.	Investigational
Canrenoic acid	The risk or severity of adverse effects can be increased when Sufentanil is combined with Canrenoic acid.	Approved, Withdrawn
Canrenone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Canrenone.	Investigational
Captopril	The risk or severity of adverse effects can be increased when Sufentanil is combined with Captopril.	Approved
Carbamazepine	The metabolism of Sufentanil can be increased when combined with Carbamazepine.	Approved, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Carbetocin is combined with Sufentanil.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Carfentanil.	Illicit, Investigational, Vet Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Carisoprodol.	Approved
Caroxazone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Caroxazone.	Withdrawn
Carteolol	Sufentanil may increase the bradycardic activities of Carteolol.	Approved
Carvedilol	Sufentanil may increase the bradycardic activities of Carvedilol.	Approved, Investigational
Celiprolol	Sufentanil may increase the bradycardic activities of Celiprolol.	Approved, Investigational
Ceritinib	Sufentanil may increase the bradycardic activities of Ceritinib.	Approved
Cetirizine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cetirizine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chloral hydrate.	Approved, Illicit, Investigational, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sufentanil.	Approved, Illicit, Investigational
Chlormezanone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlormezanone.	Approved, Investigational, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chloroprocaine.	Approved
Chlorothiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorothiazide.	Approved, Vet Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorphenamine.	Approved
Chlorphenoxamine	The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Sufentanil.	Withdrawn
Chlorphentermine	Chlorphentermine may increase the analgesic activities of Sufentanil.	Illicit, Withdrawn
Chlorproethazine	Chlorproethazine may increase the hypotensive activities of Sufentanil.	Experimental
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sufentanil.	Approved, Investigational, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorprothixene.	Approved, Investigational, Withdrawn
Chlorthalidone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorthalidone.	Approved
Chlorzoxazone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorzoxazone.	Approved
Cicletanine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cicletanine.	Investigational
Cilazapril	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Cilnidipine is combined with Sufentanil.	Approved, Investigational
Cinchocaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cinchocaine.	Approved, Vet Approved
Citalopram	Sufentanil may increase the serotonergic activities of Citalopram.	Approved
Clarithromycin	The metabolism of Sufentanil can be decreased when combined with Clarithromycin.	Approved
Clemastine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clemastine.	Approved, Investigational
Clevidipine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clevidipine.	Approved, Investigational
Clidinium	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clidinium.	Approved
Clindamycin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clindamycin.	Approved, Vet Approved
Clobazam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clobazam.	Approved, Illicit
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Sufentanil.	Approved, Investigational
Clofenamide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clofenamide.	Experimental
clomethiazole	The risk or severity of adverse effects can be increased when Sufentanil is combined with clomethiazole.	Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Clomipramine is combined with Sufentanil.	Approved, Investigational, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clonazepam.	Approved, Illicit
Clonidine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clonidine.	Approved
Clopamide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clopamide.	Experimental
Clopenthixol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clopenthixol.	Experimental
Cloranolol	Sufentanil may increase the bradycardic activities of Cloranolol.	Experimental
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Sufentanil.	Approved, Illicit
Clorexolone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clorexolone.	Experimental
Clothiapine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clothiapine.	Experimental
Clotrimazole	The metabolism of Sufentanil can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The risk or severity of adverse effects can be increased when Clozapine is combined with Sufentanil.	Approved
Cobicistat	The metabolism of Sufentanil can be decreased when combined with Cobicistat.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cocaine.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Sufentanil.	Approved, Illicit
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Sufentanil.	Approved, Investigational
Crizotinib	The metabolism of Sufentanil can be decreased when combined with Crizotinib.	Approved
Curcumin	The metabolism of Sufentanil can be decreased when combined with Curcumin.	Approved, Investigational
Cyclizine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclobenzaprine.	Approved
Cyclopenthiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclopenthiazide.	Experimental
Cyclopentolate	The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Sufentanil.	Approved
Cyclopropane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclopropane.	Experimental
Cyclosporine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyclothiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclothiazide.	Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyproheptadine.	Approved
Dabrafenib	The serum concentration of Sufentanil can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Dantrolene	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dantrolene.	Approved, Investigational
Dapagliflozin	The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Sufentanil.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dapiprazole.	Approved
Dapoxetine	Sufentanil may increase the serotonergic activities of Dapoxetine.	Investigational
Darifenacin	The risk or severity of adverse effects can be increased when Darifenacin is combined with Sufentanil.	Approved, Investigational
Darunavir	The metabolism of Sufentanil can be decreased when combined with Darunavir.	Approved
Dasatinib	The serum concentration of Sufentanil can be increased when it is combined with Dasatinib.	Approved, Investigational
Deferasirox	The serum concentration of Sufentanil can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Sufentanil can be decreased when combined with Delavirdine.	Approved
Deramciclane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Desflurane.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Desipramine.	Approved, Investigational
Desloratadine	The risk or severity of adverse effects can be increased when Desloratadine is combined with Sufentanil.	Approved, Investigational
Desmopressin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin.	Approved
Desvenlafaxine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Desvenlafaxine.	Approved, Investigational
Detomidine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Detomidine.	Vet Approved
Dexamethasone	The serum concentration of Sufentanil can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dexbrompheniramine.	Approved
Dexetimide	The risk or severity of adverse effects can be increased when Dexetimide is combined with Sufentanil.	Withdrawn
Dexmedetomidine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dexmedetomidine.	Approved, Vet Approved
Dextroamphetamine	Dextroamphetamine may increase the analgesic activities of Sufentanil.	Approved, Illicit
Dextromethorphan	The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sufentanil.	Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dextropropoxyphene.	Approved, Illicit, Investigational, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dezocine.	Approved, Investigational
Diazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Diazepam.	Approved, Illicit, Investigational, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Diclofenamide.	Approved, Investigational
Dicyclomine	The risk or severity of adverse effects can be increased when Dicyclomine is combined with Sufentanil.	Approved
Diethyl ether	The risk or severity of adverse effects can be increased when Sufentanil is combined with Diethyl ether.	Experimental
Diethylpropion	Diethylpropion may increase the analgesic activities of Sufentanil.	Approved, Illicit
Difenoxin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Difenoxin.	Approved, Illicit
Digoxin	Digoxin may increase the bradycardic activities of Sufentanil.	Approved
Dihydrocodeine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydrocodeine.	Approved, Illicit
Dihydroergotamine	The metabolism of Sufentanil can be decreased when combined with Dihydroergotamine.	Approved, Investigational
Dihydroetorphine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydromorphine.	Experimental, Illicit
Diltiazem	The metabolism of Sufentanil can be decreased when combined with Diltiazem.	Approved, Investigational
Dimenhydrinate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dimenhydrinate.	Approved
Dinutuximab	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dinutuximab.	Approved, Investigational
Diphenhydramine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenhydramine.	Approved, Investigational
Diphenoxylate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenoxylate.	Approved, Illicit
Dipyridamole	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dipyridamole.	Approved
Dixyrazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dixyrazine.	Experimental
Docusate	The therapeutic efficacy of Docusate can be decreased when used in combination with Sufentanil.	Approved
Donepezil	Sufentanil may increase the bradycardic activities of Donepezil.	Approved
Doramectin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Doramectin.	Vet Approved
Dotarizine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dotarizine.	Investigational
Doxazosin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Doxazosin.	Approved
Doxepin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Doxepin.	Approved, Investigational
Doxycycline	The metabolism of Sufentanil can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved, Vet Approved
DPDPE	The risk or severity of adverse effects can be increased when Sufentanil is combined with DPDPE.	Experimental
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved, Illicit
Dronedarone	The metabolism of Sufentanil can be decreased when combined with Dronedarone.	Approved
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved, Vet Approved
Drospirenone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Drospirenone.	Approved
Drotebanol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Drotebanol.	Experimental, Illicit
Duloxetine	Sufentanil may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dyclonine.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ecgonine.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ecopipam.	Investigational
Efavirenz	The risk or severity of adverse effects can be increased when Sufentanil is combined with Efavirenz.	Approved, Investigational
Efonidipine	The therapeutic efficacy of Efonidipine can be decreased when used in combination with Sufentanil.	Approved, Investigational
Eltanolone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Eltanolone.	Investigational
Eluxadoline	Sufentanil may increase the constipating activities of Eluxadoline.	Approved, Investigational
Emepronium	The risk or severity of adverse effects can be increased when Emepronium is combined with Sufentanil.	Experimental
Empagliflozin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Empagliflozin.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Sufentanil is combined with Enalapril.	Approved, Vet Approved
Enalaprilat	The risk or severity of adverse effects can be increased when Enalaprilat is combined with Sufentanil.	Approved
Enflurane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Enflurane.	Approved, Investigational, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Entacapone.	Approved, Investigational
Enzalutamide	The serum concentration of Sufentanil can be decreased when it is combined with Enzalutamide.	Approved
Epanolol	Sufentanil may increase the bradycardic activities of Epanolol.	Experimental
Eperisone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Eperisone.	Approved, Investigational
Epitizide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Epitizide.	Experimental
Eplerenone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Eplerenone.	Approved
Epoprostenol	The risk or severity of adverse effects can be increased when Epoprostenol is combined with Sufentanil.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Sufentanil is combined with Eprosartan.	Approved
Erythromycin	The metabolism of Sufentanil can be decreased when combined with Erythromycin.	Approved, Investigational, Vet Approved
Esatenolol	Sufentanil may increase the bradycardic activities of Esatenolol.	Experimental
Escitalopram	Sufentanil may increase the serotonergic activities of Escitalopram.	Approved, Investigational
Esmolol	Sufentanil may increase the bradycardic activities of Esmolol.	Approved
Estazolam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Estazolam.	Approved, Illicit
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Sufentanil.	Approved, Investigational
Etacrynic acid	The risk or severity of adverse effects can be increased when Sufentanil is combined with Etacrynic acid.	Approved, Investigational
Etanautine	The risk or severity of adverse effects can be increased when Etanautine is combined with Sufentanil.	Experimental
Ethanol	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethchlorvynol.	Approved, Illicit, Withdrawn
Ethopropazine	The risk or severity of adverse effects can be increased when Ethopropazine is combined with Sufentanil.	Approved
Ethosuximide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethotoin.	Approved
Ethoxzolamide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethoxzolamide.	Withdrawn
Ethyl carbamate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl carbamate.	Withdrawn
Ethyl chloride	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl chloride.	Approved, Experimental, Investigational
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethylmorphine.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Etifoxine.	Investigational, Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Etomidate.	Approved
Etoperidone	Sufentanil may increase the serotonergic activities of Etoperidone.	Withdrawn
Etorphine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Etorphine.	Illicit, Vet Approved
Etybenzatropine	The risk or severity of adverse effects can be increased when Etybenzatropine is combined with Sufentanil.	Experimental
Ezogabine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ezogabine.	Approved, Investigational
Felbamate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Felbamate.	Approved
Felodipine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Felodipine.	Approved, Investigational
Fencamfamine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fencamfamine.	Approved, Illicit, Withdrawn
Fenoldopam	The risk or severity of adverse effects can be increased when Fenoldopam is combined with Sufentanil.	Approved
Fenquizone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fenquizone.	Experimental
Fentanyl	The risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Sufentanil.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Sufentanil.	Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fexofenadine.	Approved, Investigational
Fimasartan	The risk or severity of adverse effects can be increased when Fimasartan is combined with Sufentanil.	Approved, Investigational
Fingolimod	Sufentanil may increase the bradycardic activities of Fingolimod.	Approved, Investigational
Flavoxate	The risk or severity of adverse effects can be increased when Flavoxate is combined with Sufentanil.	Approved
Flibanserin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Flibanserin.	Approved, Investigational
Fluanisone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fluanisone.	Experimental
Fluconazole	The metabolism of Sufentanil can be decreased when combined with Fluconazole.	Approved, Investigational
Fludiazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fludiazepam.	Approved, Illicit
Flunarizine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Flunitrazepam.	Approved, Illicit
Fluoxetine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Flupentixol.	Approved, Investigational, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Fluphenazine is combined with Sufentanil.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Flurazepam is combined with Sufentanil.	Approved, Illicit, Investigational
Fluspirilene	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fluspirilene.	Approved, Investigational
Fluticasone propionate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fluticasone propionate.	Approved
Fluvoxamine	The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sufentanil.	Approved, Investigational
Fosamprenavir	The metabolism of Sufentanil can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Sufentanil can be increased when it is combined with Fosaprepitant.	Approved
Fosinopril	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fosinopril.	Approved
Fosphenytoin	The metabolism of Sufentanil can be increased when combined with Fosphenytoin.	Approved, Investigational
Fospropofol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fospropofol.	Approved, Illicit, Investigational
Furazolidone	Furazolidone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Sufentanil.	Approved, Investigational, Vet Approved
Furosemide	The therapeutic efficacy of Furosemide can be decreased when used in combination with Sufentanil.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Sufentanil can be increased when it is combined with Fusidic Acid.	Approved, Investigational
Gabapentin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Gabapentin.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Gabapentin Enacarbil.	Approved, Investigational
Galantamine	Galantamine may increase the bradycardic activities of Sufentanil.	Approved
Gallamine	The risk or severity of adverse effects can be increased when Gallamine is combined with Sufentanil.	Experimental
Gallamine Triethiodide	The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Sufentanil.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Sufentanil is combined with Gamma Hydroxybutyric Acid.	Approved, Illicit, Investigational
Gepefrine	Gepefrine may increase the analgesic activities of Sufentanil.	Experimental
Gepirone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Gepirone.	Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Glutethimide.	Approved, Illicit
Glycerin	The therapeutic efficacy of Glycerin can be decreased when used in combination with Sufentanil.	Approved, Investigational
Glycopyrronium	The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Sufentanil.	Approved, Investigational, Vet Approved
Guanfacine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Halazepam.	Approved, Illicit, Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Haloperidol is combined with Sufentanil.	Approved
Halothane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Halothane.	Approved, Vet Approved
Harmaline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Harmaline.	Experimental
Heroin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Heroin.	Approved, Illicit, Investigational
Hexobarbital	The risk or severity of adverse effects can be increased when Sufentanil is combined with Hexobarbital.	Approved
Homatropine	The risk or severity of adverse effects can be increased when Homatropine is combined with Sufentanil.	Approved
Hydracarbazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Hydracarbazine.	Experimental
Hydralazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Hydralazine.	Approved
Hydrochlorothiazide	The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Sufentanil.	Approved, Vet Approved
Hydrocodone	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydroflumethiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Hydroflumethiazide.	Approved, Investigational
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sufentanil.	Approved, Illicit
Hydroxyamphetamine	Hydroxyamphetamine may increase the analgesic activities of Sufentanil.	Approved
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved
Hyoscyamine	The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Sufentanil.	Approved
Ibopamine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ibopamine.	Experimental
Idelalisib	The metabolism of Sufentanil can be decreased when combined with Idelalisib.	Approved
Iloperidone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Iloperidone.	Approved
Iloprost	The risk or severity of adverse effects can be increased when Iloprost is combined with Sufentanil.	Approved, Investigational
Imatinib	The metabolism of Sufentanil can be decreased when combined with Imatinib.	Approved
Imidapril	The risk or severity of adverse effects can be increased when Imidapril is combined with Sufentanil.	Investigational
Imipramine	The risk or severity of adverse effects can be increased when Imipramine is combined with Sufentanil.	Approved
Indalpine	Sufentanil may increase the serotonergic activities of Indalpine.	Investigational, Withdrawn
Indapamide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Indapamide.	Approved
Indenolol	Sufentanil may increase the bradycardic activities of Indenolol.	Withdrawn
Indinavir	The metabolism of Sufentanil can be decreased when combined with Indinavir.	Approved
Indiplon	The risk or severity of adverse effects can be increased when Sufentanil is combined with Indiplon.	Investigational
Indoramin	The risk or severity of adverse effects can be increased when Indoramin is combined with Sufentanil.	Withdrawn
Iofetamine I-123	Iofetamine I-123 may increase the analgesic activities of Sufentanil.	Approved
Ipratropium	The risk or severity of adverse effects can be increased when Ipratropium is combined with Sufentanil.	Approved
Iproclozide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Iproclozide.	Withdrawn
Iproniazid	Iproniazid may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Sufentanil.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Sufentanil is combined with Irbesartan.	Approved, Investigational
Isavuconazole	The serum concentration of Sufentanil can be increased when it is combined with Isavuconazole.	Approved, Investigational
Isavuconazonium	The metabolism of Sufentanil can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isocarboxazid	The risk or severity of adverse effects can be increased when Sufentanil is combined with Isocarboxazid.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Isoflurane.	Approved, Vet Approved
Isosorbide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Isosorbide.	Approved, Investigational
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Isosorbide Dinitrate.	Approved, Investigational
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Isosorbide Mononitrate.	Approved
Isoxsuprine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Isradipine.	Approved, Investigational
Itraconazole	The metabolism of Sufentanil can be decreased when combined with Itraconazole.	Approved, Investigational
Ivabradine	Sufentanil may increase the bradycardic activities of Ivabradine.	Approved
Ivacaftor	The serum concentration of Sufentanil can be increased when it is combined with Ivacaftor.	Approved
Ketamine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ketamine.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ketazolam.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ketobemidone.	Approved, Investigational
Ketoconazole	The metabolism of Sufentanil can be decreased when combined with Ketoconazole.	Approved, Investigational
Labetalol	Sufentanil may increase the bradycardic activities of Labetalol.	Approved
Lacidipine	Sufentanil may increase the hypotensive activities of Lacidipine.	Approved, Investigational
Lacosamide	Sufentanil may increase the atrioventricular blocking (AV block) activities of Lacosamide.	Approved
Lactulose	The therapeutic efficacy of Lactulose can be decreased when used in combination with Sufentanil.	Approved
Lamotrigine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Lamotrigine.	Approved, Investigational
Landiolol	Sufentanil may increase the bradycardic activities of Landiolol.	Investigational
Lanreotide	Sufentanil may increase the bradycardic activities of Lanreotide.	Approved
Lercanidipine	The risk or severity of adverse effects can be increased when Lercanidipine is combined with Sufentanil.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Levetiracetam.	Approved, Investigational
Levobetaxolol	Sufentanil may increase the bradycardic activities of Levobetaxolol.	Approved, Investigational
Levobunolol	Sufentanil may increase the bradycardic activities of Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Levobupivacaine.	Approved, Investigational
Levocabastine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Levocabastine.	Approved, Investigational
Levocetirizine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Levocetirizine.	Approved
Levodopa	Sufentanil may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Levomethadyl Acetate.	Approved, Investigational
Levomilnacipran	Sufentanil may increase the serotonergic activities of Levomilnacipran.	Approved, Investigational
Levorphanol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Levorphanol.	Approved
Levosimendan	The risk or severity of adverse effects can be increased when Levosimendan is combined with Sufentanil.	Approved, Investigational
Lisdexamfetamine	Lisdexamfetamine may increase the analgesic activities of Sufentanil.	Approved, Investigational
Lisinopril	The risk or severity of adverse effects can be increased when Sufentanil is combined with Lisinopril.	Approved, Investigational
Lithium cation	The risk or severity of adverse effects can be increased when Sufentanil is combined with Lithium.	Experimental
Lofentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Lofentanil.	Illicit
Lofexidine	The therapeutic efficacy of Sufentanil can be increased when used in combination with Lofexidine.	Approved, Investigational
Lopinavir	The metabolism of Sufentanil can be decreased when combined with Lopinavir.	Approved
Loprazolam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Loprazolam.	Experimental
Loratadine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Loratadine.	Approved, Investigational
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Sufentanil.	Approved
Lormetazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Lormetazepam.	Approved
Lorpiprazole	The serum concentration of Sufentanil can be increased when it is combined with Lorpiprazole.	Approved
Losartan	The risk or severity of adverse effects can be increased when Sufentanil is combined with Losartan.	Approved
Lovastatin	The metabolism of Sufentanil can be decreased when combined with Lovastatin.	Approved, Investigational
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Sufentanil.	Approved
Lucinactant	Sufentanil may increase the bradycardic activities of Lucinactant.	Approved, Investigational
Luliconazole	The serum concentration of Sufentanil can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The metabolism of Sufentanil can be increased when combined with Lumacaftor.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Lurasidone.	Approved, Investigational
Magnesium carbonate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Magnesium carbonate.	Approved, Investigational
Magnesium citrate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Magnesium citrate.	Approved
Magnesium hydroxide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Magnesium hydroxide.	Approved, Investigational
Magnesium sulfate	The therapeutic efficacy of Sufentanil can be increased when used in combination with Magnesium sulfate.	Approved, Investigational, Vet Approved
Magnesium Trisilicate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Magnesium Trisilicate.	Approved
Mannitol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Mannitol.	Approved, Investigational
Maprotiline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Maprotiline.	Approved, Investigational
Mazaticol	The risk or severity of adverse effects can be increased when Mazaticol is combined with Sufentanil.	Experimental
Mebanazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Mebanazine.	Withdrawn
Mebicar	The risk or severity of adverse effects can be increased when Sufentanil is combined with Mebicar.	Experimental
Mebutizide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Mebutizide.	Experimental
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Sufentanil.	Approved, Investigational
Meclizine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Meclizine.	Approved
Medazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Medazepam.	Experimental
Medetomidine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Medetomidine.	Vet Approved
Mefruside	The risk or severity of adverse effects can be increased when Sufentanil is combined with Mefruside.	Experimental
Melatonin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Melatonin.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Melperone.	Approved, Investigational
Mephedrone	Mephedrone may increase the analgesic activities of Sufentanil.	Investigational
Mephentermine	Mephentermine may increase the analgesic activities of Sufentanil.	Approved
Mepindolol	Sufentanil may increase the bradycardic activities of Mepindolol.	Experimental
Mepivacaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Mepivacaine.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Sufentanil.	Approved, Illicit
Meptazinol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Meptazinol.	Experimental
Mersalyl	The risk or severity of adverse effects can be increased when Sufentanil is combined with Mersalyl.	Approved
Mesoridazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Mesoridazine.	Approved, Investigational
Metaxalone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Metaxalone.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Sufentanil.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methadyl Acetate.	Approved, Illicit
Methamphetamine	Methamphetamine may increase the analgesic activities of Sufentanil.	Approved, Illicit
Methantheline	The risk or severity of adverse effects can be increased when Methantheline is combined with Sufentanil.	Approved, Investigational
Methapyrilene	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methaqualone.	Illicit, Withdrawn
Methazolamide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methazolamide.	Approved
Methocarbamol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Sufentanil.	Approved
Methotrimeprazine	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved, Investigational
Methoxyflurane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methoxyflurane.	Approved, Investigational, Vet Approved
Methoxyphenamine	Methoxyphenamine may increase the analgesic activities of Sufentanil.	Experimental
Methscopolamine	The risk or severity of adverse effects can be increased when Methscopolamine is combined with Sufentanil.	Approved
Methsuximide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methsuximide.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methyclothiazide.	Approved
Methyldopa	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methyldopa.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methylecgonine.	Experimental
Methylene blue	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methylene blue.	Approved, Investigational
Methylphenobarbital	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methylphenobarbital.	Approved
Methylscopolamine bromide	The risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Sufentanil.	Approved
Meticrane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Meticrane.	Experimental
Metipranolol	Sufentanil may increase the bradycardic activities of Metipranolol.	Approved
Metixene	The risk or severity of adverse effects can be increased when Metixene is combined with Sufentanil.	Approved
Metoclopramide	The risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Sufentanil.	Approved, Investigational
Metolazone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Metolazone.	Approved
Metoprolol	Sufentanil may increase the bradycardic activities of Metoprolol.	Approved, Investigational
Metyrosine	Sufentanil may increase the sedative activities of Metyrosine.	Approved
Mibefradil	The metabolism of Sufentanil can be decreased when combined with Mibefradil.	Investigational, Withdrawn
Miconazole	The metabolism of Sufentanil can be decreased when combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Sufentanil.	Approved, Illicit
Midomafetamine	Midomafetamine may increase the analgesic activities of Sufentanil.	Experimental, Illicit, Investigational
Mifepristone	The serum concentration of Sufentanil can be increased when it is combined with Mifepristone.	Approved, Investigational
Milnacipran	Sufentanil may increase the serotonergic activities of Milnacipran.	Approved, Investigational
Minaprine	Minaprine may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Sufentanil.	Approved
Mineral oil	The therapeutic efficacy of Mineral oil can be decreased when used in combination with Sufentanil.	Approved, Vet Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved, Investigational
Minoxidil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Minoxidil.	Approved, Investigational
Mirtazapine	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Mitotane	The serum concentration of Sufentanil can be decreased when it is combined with Mitotane.	Approved
MMDA	MMDA may increase the analgesic activities of Sufentanil.	Experimental, Illicit
Moclobemide	Moclobemide may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Sufentanil.	Approved, Investigational
Moexipril	The risk or severity of adverse effects can be increased when Sufentanil is combined with Moexipril.	Approved
Molindone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Molindone.	Approved
Moricizine	Moricizine may increase the hypotensive activities of Sufentanil.	Approved, Investigational, Withdrawn
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Sufentanil.	Approved, Investigational
Moxonidine	The risk or severity of adverse effects can be increased when Moxonidine is combined with Sufentanil.	Approved, Investigational
Muzolimine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Muzolimine.	Experimental
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved, Investigational
Nadolol	Sufentanil may increase the bradycardic activities of Nadolol.	Approved
Nalbuphine	Nalbuphine may decrease the analgesic activities of Sufentanil.	Approved
Naltrexone	The therapeutic efficacy of Sufentanil can be decreased when used in combination with Naltrexone.	Approved, Investigational, Vet Approved
Nebivolol	Sufentanil may increase the bradycardic activities of Nebivolol.	Approved, Investigational
Nefazodone	The metabolism of Sufentanil can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The metabolism of Sufentanil can be decreased when combined with Nelfinavir.	Approved
Neomycin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Neomycin.	Approved, Vet Approved
Nesiritide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Nesiritide.	Approved, Investigational
Netupitant	The serum concentration of Sufentanil can be increased when it is combined with Netupitant.	Approved, Investigational
Nevirapine	The metabolism of Sufentanil can be increased when combined with Nevirapine.	Approved
Nialamide	Nialamide may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Sufentanil.	Withdrawn
Nicardipine	The risk or severity of adverse effects can be increased when Nicardipine is combined with Sufentanil.	Approved, Investigational
Nicorandil	Nicorandil may increase the hypotensive activities of Sufentanil.	Approved, Investigational
Nifedipine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Nifedipine.	Approved
Nilotinib	The metabolism of Sufentanil can be decreased when combined with Nilotinib.	Approved, Investigational
Nilvadipine	The risk or severity of adverse effects can be increased when Nilvadipine is combined with Sufentanil.	Approved, Investigational
Nimodipine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Nimodipine.	Approved, Investigational
Nisoldipine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Nisoldipine.	Approved
Nitrazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrazepam.	Approved
Nitrendipine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sufentanil.	Approved, Investigational
Nitric Oxide	The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sufentanil.	Approved
Nitroglycerin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Nitroglycerin.	Approved, Investigational
Nitroprusside	The risk or severity of adverse effects can be increased when Sufentanil is combined with Nitroprusside.	Approved, Investigational
Nitrous acid	The risk or severity of adverse effects can be increased when Nitrous acid is combined with Sufentanil.	Approved, Investigational
Nitrous oxide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrous oxide.	Approved, Vet Approved
Nordazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Nordazepam.	Approved
Norflurane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Norflurane.	Approved, Investigational
Normethadone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Normethadone.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Nortriptyline.	Approved
Obinutuzumab	The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sufentanil.	Approved, Investigational
Octamoxin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Octamoxin.	Withdrawn
Octreotide	Octreotide may increase the bradycardic activities of Sufentanil.	Approved, Investigational
Olanzapine	The risk or severity of adverse effects can be increased when Olanzapine is combined with Sufentanil.	Approved, Investigational
Olaparib	The metabolism of Sufentanil can be decreased when combined with Olaparib.	Approved
Olmesartan	The risk or severity of adverse effects can be increased when Sufentanil is combined with Olmesartan.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Olopatadine.	Approved
Ondansetron	The risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Sufentanil.	Approved
Opium	The risk or severity of adverse effects can be increased when Sufentanil is combined with Opium.	Approved, Illicit
Orphenadrine	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Sufentanil is combined with Osanetant.	Investigational
Osimertinib	The serum concentration of Sufentanil can be increased when it is combined with Osimertinib.	Approved
Otilonium	The risk or severity of adverse effects can be increased when Otilonium is combined with Sufentanil.	Experimental, Investigational
Oxazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxazepam.	Approved
Oxitropium	The risk or severity of adverse effects can be increased when Oxitropium is combined with Sufentanil.	Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxybuprocaine.	Approved, Investigational
Oxybutynin	The risk or severity of adverse effects can be increased when Oxybutynin is combined with Sufentanil.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Sufentanil.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxymorphone.	Approved, Investigational, Vet Approved
Oxyphenonium	The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Sufentanil.	Approved
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Sufentanil.	Approved, Vet Approved
Palbociclib	The serum concentration of Sufentanil can be increased when it is combined with Palbociclib.	Approved, Investigational
Paliperidone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Paliperidone.	Approved
Pancuronium	The risk or severity of adverse effects can be increased when Pancuronium is combined with Sufentanil.	Approved
Papaverine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Papaverine.	Approved, Investigational
Paraldehyde	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved, Investigational
Pargyline	Pargyline may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Sufentanil.	Approved
Paromomycin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Paromomycin.	Approved, Investigational
Paroxetine	The risk or severity of adverse effects can be increased when Paroxetine is combined with Sufentanil.	Approved, Investigational
Pasireotide	Sufentanil may increase the bradycardic activities of Pasireotide.	Approved
Pegvisomant	The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Sufentanil.	Approved
Penbutolol	Sufentanil may increase the bradycardic activities of Penbutolol.	Approved, Investigational
Penfluridol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Penfluridol.	Experimental
Pentazocine	Pentazocine may decrease the analgesic activities of Sufentanil.	Approved, Vet Approved
Pentobarbital	The metabolism of Sufentanil can be increased when combined with Pentobarbital.	Approved, Investigational, Vet Approved
Pentolinium	The risk or severity of adverse effects can be increased when Pentolinium is combined with Sufentanil.	Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved
Perazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Perazine.	Approved, Investigational
Perindopril	The risk or severity of adverse effects can be increased when Sufentanil is combined with Perindopril.	Approved
Perospirone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Perphenazine.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Sufentanil.	Approved
Phenazocine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Phenazocine.	Experimental
Phenelzine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Phenelzine.	Approved
Phenglutarimide	The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Sufentanil.	Experimental
Phenibut	The risk or severity of adverse effects can be increased when Sufentanil is combined with Phenibut.	Experimental
Pheniprazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Pheniprazine.	Withdrawn
Phenobarbital	Phenobarbital may increase the hypotensive activities of Sufentanil.	Approved, Investigational
Phenoperidine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Phenoperidine.	Experimental
Phenoxybenzamine	The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sufentanil.	Approved
Phenoxyethanol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Phenoxyethanol.	Approved
Phenoxypropazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Phenoxypropazine.	Withdrawn
Phentermine	Phentermine may increase the analgesic activities of Sufentanil.	Approved, Illicit
Phentolamine	The risk or severity of adverse effects can be increased when Phentolamine is combined with Sufentanil.	Approved
Phenytoin	The metabolism of Sufentanil can be increased when combined with Phenytoin.	Approved, Vet Approved
Pimozide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Pimozide.	Approved
Pindolol	Sufentanil may increase the bradycardic activities of Pindolol.	Approved, Investigational
Pipamperone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Pipamperone.	Approved, Investigational
Pipecuronium	The risk or severity of adverse effects can be increased when Pipecuronium is combined with Sufentanil.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Pipotiazine.	Approved, Investigational
Pirenzepine	The risk or severity of adverse effects can be increased when Pirenzepine is combined with Sufentanil.	Approved
Piretanide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Piretanide.	Approved
Piritramide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Piritramide.	Approved, Investigational
Pirlindole	Pirlindole may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Sufentanil.	Approved
Pitolisant	The serum concentration of Sufentanil can be decreased when it is combined with Pitolisant.	Approved, Investigational
Pivhydrazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Pivhydrazine.	Withdrawn
Pizotifen	The risk or severity of adverse effects can be increased when Sufentanil is combined with Pizotifen.	Approved
Platelet Activating Factor	Sufentanil may increase the bradycardic activities of Platelet Activating Factor.	Experimental
Polymyxin B Sulfate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Polymyxin B Sulfate.	Approved, Vet Approved
Polythiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Polythiazide.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Pomalidomide.	Approved
Poractant alfa	Sufentanil may increase the bradycardic activities of Poractant alfa.	Approved
Posaconazole	The metabolism of Sufentanil can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Potassium cation	The risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium.	Approved, Investigational
Potassium Citrate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium Citrate.	Approved, Investigational, Vet Approved
Practolol	Sufentanil may increase the bradycardic activities of Practolol.	Approved
Pramipexole	Sufentanil may increase the sedative activities of Pramipexole.	Approved, Investigational
Prazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Prazepam.	Approved, Illicit
Prazosin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Prazosin.	Approved
Pregabalin	The therapeutic efficacy of Sufentanil can be increased when used in combination with Pregabalin.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Prilocaine.	Approved
Primidone	The metabolism of Sufentanil can be increased when combined with Primidone.	Approved, Vet Approved
Procaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Procaine.	Approved, Investigational, Vet Approved
Procarbazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Procarbazine.	Approved, Investigational
Prochlorperazine	The risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Sufentanil.	Approved, Vet Approved
Procyclidine	The risk or severity of adverse effects can be increased when Procyclidine is combined with Sufentanil.	Approved
Promazine	The risk or severity of adverse effects can be increased when Promazine is combined with Sufentanil.	Approved, Vet Approved
Promethazine	The risk or severity of hypotension and central nervous system depression can be increased when Promethazine is combined with Sufentanil.	Approved, Investigational
Propafenone	Sufentanil may increase the bradycardic activities of Propafenone.	Approved
Propanidid	The risk or severity of adverse effects can be increased when Sufentanil is combined with Propanidid.	Experimental
Propantheline	The risk or severity of adverse effects can be increased when Propantheline is combined with Sufentanil.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Proparacaine.	Approved, Vet Approved
Propericiazine	Propericiazine may increase the hypotensive activities of Sufentanil.	Approved, Investigational
Propiopromazine	Propiopromazine may increase the hypotensive activities of Sufentanil.	Vet Approved
Propiverine	The risk or severity of adverse effects can be increased when Propiverine is combined with Sufentanil.	Approved, Investigational
Propofol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Propofol.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Propoxycaine.	Approved
Propranolol	Sufentanil may increase the bradycardic activities of Propranolol.	Approved, Investigational
Protriptyline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Protriptyline.	Approved
Proxibarbal	The risk or severity of adverse effects can be increased when Sufentanil is combined with Proxibarbal.	Experimental
PSD502	The risk or severity of adverse effects can be increased when Sufentanil is combined with PSD502.	Investigational
Pseudoephedrine	Pseudoephedrine may increase the analgesic activities of Sufentanil.	Approved
Pyrantel	The risk or severity of adverse effects can be increased when Sufentanil is combined with Pyrantel.	Approved, Vet Approved
Quazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Quazepam.	Approved, Illicit
Quetiapine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Quetiapine.	Approved
Quinapril	The risk or severity of adverse effects can be increased when Sufentanil is combined with Quinapril.	Approved, Investigational
Quinethazone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Quinethazone.	Approved
Quinidine	The risk or severity of adverse effects can be increased when Quinidine is combined with Sufentanil.	Approved, Investigational
Quinisocaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Quinisocaine.	Experimental
Raclopride	The risk or severity of adverse effects can be increased when Sufentanil is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ramelteon.	Approved, Investigational
Ramipril	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ramipril.	Approved
Ramosetron	Sufentanil may increase the constipating activities of Ramosetron.	Approved, Investigational
Ranolazine	The metabolism of Sufentanil can be decreased when combined with Ranolazine.	Approved, Investigational
Rasagiline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Rasagiline.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Remifentanil.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Sufentanil is combined with Remoxipride.	Approved, Withdrawn
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Sufentanil.	Approved, Investigational
Rifabutin	The metabolism of Sufentanil can be increased when combined with Rifabutin.	Approved, Investigational
Rifampicin	The metabolism of Sufentanil can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Sufentanil can be increased when combined with Rifapentine.	Approved, Investigational
Rilpivirine	The serum concentration of Sufentanil can be decreased when it is combined with Rilpivirine.	Approved
Riociguat	The risk or severity of adverse effects can be increased when Sufentanil is combined with Riociguat.	Approved
Risperidone	Sufentanil may increase the hypotensive activities of Risperidone.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ritanserin.	Investigational
Ritobegron	Ritobegron may increase the analgesic activities of Sufentanil.	Investigational
Rivastigmine	Sufentanil may increase the bradycardic activities of Rivastigmine.	Approved, Investigational
Rizatriptan	The risk or severity of adverse effects can be increased when Rizatriptan is combined with Sufentanil.	Approved
Rolofylline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Rolofylline.	Investigational
Romifidine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Romifidine.	Vet Approved
Ropinirole	Sufentanil may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ropivacaine.	Approved
Rotigotine	Sufentanil may increase the sedative activities of Rotigotine.	Approved
Rucaparib	The metabolism of Sufentanil can be decreased when combined with Rucaparib.	Approved, Investigational
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Sufentanil.	Approved
Ruxolitinib	Ruxolitinib may increase the bradycardic activities of Sufentanil.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Sacubitril is combined with Sufentanil.	Approved
Safrazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Safrazine.	Withdrawn
Saquinavir	The metabolism of Sufentanil can be decreased when combined with Saquinavir.	Approved, Investigational
Sarilumab	The therapeutic efficacy of Sufentanil can be decreased when used in combination with Sarilumab.	Approved, Investigational
Scopolamine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Scopolamine.	Approved, Investigational
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Sufentanil.	Approved, Vet Approved
Selegiline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Selegiline.	Approved, Investigational, Vet Approved
Sepranolone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Sepranolone.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Sufentanil is combined with Sertindole.	Approved, Investigational, Withdrawn
Sertraline	Sufentanil may increase the serotonergic activities of Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Sevoflurane.	Approved, Vet Approved
Sildenafil	The metabolism of Sufentanil can be decreased when combined with Sildenafil.	Approved, Investigational
Siltuximab	The serum concentration of Sufentanil can be decreased when it is combined with Siltuximab.	Approved, Investigational
Simeprevir	The serum concentration of Sufentanil can be increased when it is combined with Simeprevir.	Approved
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved
Sodium phosphate, monobasic	The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Sufentanil.	Approved
Solifenacin	The risk or severity of adverse effects can be increased when Solifenacin is combined with Sufentanil.	Approved
Sotalol	Sufentanil may increase the bradycardic activities of Sotalol.	Approved
Spiradoline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Spiradoline.	Investigational
Spironolactone	The therapeutic efficacy of Spironolactone can be decreased when used in combination with Sufentanil.	Approved
St. John's Wort	The serum concentration of Sufentanil can be decreased when it is combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stiripentol	The serum concentration of Sufentanil can be increased when it is combined with Stiripentol.	Approved
Streptokinase	The risk or severity of adverse effects can be increased when Streptokinase is combined with Sufentanil.	Approved, Investigational
Succinylcholine	Succinylcholine may increase the bradycardic activities of Sufentanil.	Approved
Sulfisoxazole	The metabolism of Sufentanil can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulpiride	The risk or severity of adverse effects can be increased when Sufentanil is combined with Sulpiride.	Approved, Investigational
Sultopride	The risk or severity of adverse effects can be increased when Sufentanil is combined with Sultopride.	Experimental
Sumatriptan	The risk or severity of adverse effects can be increased when Sumatriptan is combined with Sufentanil.	Approved, Investigational
Suvorexant	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved, Investigational
Talinolol	Sufentanil may increase the bradycardic activities of Talinolol.	Investigational
Tamsulosin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tamsulosin.	Approved, Investigational
Tandospirone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tasimelteon.	Approved, Investigational
Telaprevir	The metabolism of Sufentanil can be decreased when combined with Telaprevir.	Approved, Withdrawn
Telithromycin	The metabolism of Sufentanil can be decreased when combined with Telithromycin.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Sufentanil is combined with Telmisartan.	Approved, Investigational
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Sufentanil.	Approved, Investigational
Terazosin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Terazosin.	Approved
Terbutaline	Sufentanil may increase the bradycardic activities of Terbutaline.	Approved
Tertatolol	Sufentanil may increase the bradycardic activities of Tertatolol.	Experimental
Tetrabenazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrabenazine.	Approved, Investigational
Tetracaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tetracaine.	Approved, Vet Approved
Tetracycline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tetracycline.	Approved, Vet Approved
Tetrahydropalmatine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrahydropalmatine.	Investigational
Tetrodotoxin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrodotoxin.	Investigational
Thalidomide	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Theobromine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Theobromine.	Approved, Investigational
Thiamylal	The risk or severity of adverse effects can be increased when Sufentanil is combined with Thiamylal.	Approved, Vet Approved
Thiazinam	Thiazinam may increase the hypotensive activities of Sufentanil.	Experimental
Thiethylperazine	Thiethylperazine may increase the hypotensive activities of Sufentanil.	Withdrawn
Thiopental	The risk or severity of adverse effects can be increased when Sufentanil is combined with Thiopental.	Approved, Vet Approved
Thioproperazine	Thioproperazine may increase the hypotensive activities of Sufentanil.	Approved
Thioridazine	The risk or severity of adverse effects can be increased when Thioridazine is combined with Sufentanil.	Approved, Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Sufentanil is combined with Thiothixene.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tiagabine.	Approved, Investigational
Tiapride	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tiapride.	Approved, Investigational
Ticlopidine	The metabolism of Sufentanil can be decreased when combined with Ticlopidine.	Approved
Ticrynafen	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ticrynafen.	Withdrawn
Tiletamine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tiletamine.	Vet Approved
Tilidine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tilidine.	Experimental
Timolol	Sufentanil may increase the bradycardic activities of Timolol.	Approved
Tiotropium	The risk or severity of adverse effects can be increased when Tiotropium is combined with Sufentanil.	Approved
Tizanidine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tizanidine.	Approved, Investigational
Tocilizumab	The serum concentration of Sufentanil can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	Tofacitinib may increase the bradycardic activities of Sufentanil.	Approved, Investigational
Tolazoline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tolazoline.	Approved, Vet Approved
Tolcapone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tolcapone.	Approved, Withdrawn
Toloxatone	Toloxatone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Sufentanil.	Approved
Tolterodine	The risk or severity of adverse effects can be increased when Tolterodine is combined with Sufentanil.	Approved, Investigational
Tolvaptan	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tolvaptan.	Approved
Topiramate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Topiramate.	Approved
Torasemide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Torasemide.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Sufentanil.	Approved, Investigational
Trandolapril	The risk or severity of adverse effects can be increased when Sufentanil is combined with Trandolapril.	Approved
Tranylcypromine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tranylcypromine.	Approved, Investigational
Trazodone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Trazodone.	Approved, Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tretinoin.	Approved, Investigational, Nutraceutical
Triamterene	The risk or severity of adverse effects can be increased when Sufentanil is combined with Triamterene.	Approved
Triazolam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Triazolam.	Approved, Investigational
Tricaine methanesulfonate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tricaine methanesulfonate.	Vet Approved
Trichlormethiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Trichlormethiazide.	Approved, Vet Approved
Trichloroethylene	The risk or severity of adverse effects can be increased when Sufentanil is combined with Trichloroethylene.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Trifluoperazine.	Approved, Investigational
Trifluperidol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Trifluperidol.	Experimental
Triflupromazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Triflupromazine.	Approved, Vet Approved
Trihexyphenidyl	The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Sufentanil.	Approved
Trimebutine	The risk or severity of adverse effects can be increased when Trimebutine is combined with Sufentanil.	Approved
Trimethadione	The risk or severity of adverse effects can be increased when Sufentanil is combined with Trimethadione.	Approved
Trimethaphan	The risk or severity of adverse effects can be increased when Trimethaphan is combined with Sufentanil.	Approved, Investigational
Trimipramine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Triprolidine.	Approved
Tropatepine	The risk or severity of adverse effects can be increased when Tropatepine is combined with Sufentanil.	Experimental
Tropicamide	The risk or severity of adverse effects can be increased when Tropicamide is combined with Sufentanil.	Approved, Investigational
Trospium	The risk or severity of adverse effects can be increased when Trospium is combined with Sufentanil.	Approved
Tubocurarine	The risk or severity of adverse effects can be increased when Tubocurarine is combined with Sufentanil.	Approved
Ularitide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ularitide.	Investigational
Umeclidinium	The risk or severity of adverse effects can be increased when Umeclidinium is combined with Sufentanil.	Approved
Valproic Acid	The risk or severity of adverse effects can be increased when Sufentanil is combined with Valproic Acid.	Approved, Investigational
Valsartan	The risk or severity of adverse effects can be increased when Sufentanil is combined with Valsartan.	Approved, Investigational
Vancomycin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Vancomycin.	Approved
Vecuronium	The risk or severity of adverse effects can be increased when Sufentanil is combined with Vecuronium.	Approved
Vemurafenib	The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sufentanil.	Approved
Venlafaxine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Venlafaxine.	Approved
Veralipride	The risk or severity of adverse effects can be increased when Sufentanil is combined with Veralipride.	Experimental
Verapamil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Verapamil.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Vigabatrin.	Approved
Vinpocetine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Vinpocetine.	Investigational
Vinyl ether	The risk or severity of adverse effects can be increased when Sufentanil is combined with Vinyl ether.	Experimental
Voriconazole	The metabolism of Sufentanil can be decreased when combined with Voriconazole.	Approved, Investigational
Vortioxetine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Vortioxetine.	Approved, Investigational
Xenon	The risk or severity of adverse effects can be increased when Sufentanil is combined with Xenon.	Experimental
Xipamide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Xipamide.	Experimental
Xylazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Xylazine.	Vet Approved
Zaleplon	The risk or severity of adverse effects can be increased when Sufentanil is combined with Zaleplon.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ziconotide.	Approved
Zimelidine	Sufentanil may increase the serotonergic activities of Zimelidine.	Withdrawn
Ziprasidone	The metabolism of Sufentanil can be decreased when combined with Ziprasidone.	Approved
Zolazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Zolazepam.	Vet Approved
Zolmitriptan	The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sufentanil.	Approved, Investigational
Zolpidem	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Zopiclone.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Zotepine.	Approved, Investigational, Withdrawn
Zuclopenthixol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Zuclopenthixol.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Jacob Mathew, J. Killgore, "New methods for the synthesis of alfentanil, sufentanil, and remifentanil." U.S. Patent US20060149071, issued July 06, 2006.

US20060149071

General References

Not Available

External Links

Human Metabolome Database: HMDB0014846
KEGG Drug: D05938
KEGG Compound: C08022
PubChem Compound: 41693
PubChem Substance: 46504737
ChemSpider: 38043
BindingDB: 94503
ChEBI: 9316
ChEMBL: CHEMBL658
Therapeutic Targets Database: DAP000357
PharmGKB: PA451527
IUPHAR: 3534
Guide to Pharmacology: GtP Drug Page
Drugs.com: Drugs.com Drug Page
Wikipedia: Sufentanil

ATC Codes

N01AH03 — Sufentanil

AHFS Codes

28:08.08 — Opiate Agonists

MSDS

Download (47.6 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Basic Science	Plasma Concentrations	1
1, 2	Terminated	Treatment	Opioids / Pain	1
2	Completed	Treatment	Anaesthesia therapy	1
2	Completed	Treatment	Major Upper or Lower Abdominal Surgery	1
2	Completed	Treatment	Pain	1
2	Completed	Treatment	Pregnant Women	1
2	Not Yet Recruiting	Treatment	Head Trauma	1
2	Recruiting	Treatment	Prenatal Diagnosis	1
2	Withdrawn	Treatment	Pain, Chronic	1
2, 3	Active Not Recruiting	Treatment	Cerebral Hypoperfusion / Intubation, Endotracheal / Premedication	1
2, 3	Active Not Recruiting	Treatment	Intubation, Endotracheal / Premedication	1
2, 3	Completed	Supportive Care	Healthy Volunteers / Pelvic Floor Disorders / Prolonged Labour	1
2, 3	Recruiting	Treatment	Myocardial Injury	1
3	Completed	Prevention	Normal Pregnancies	1
3	Completed	Treatment	Child Comfort / Intensive Care Units / Morphine / Pediatric	1
3	Completed	Treatment	Moderate-to-severe Acute Pain	1
3	Completed	Treatment	Pain, Acute	1
3	Completed	Treatment	Post Operative Pain	1
3	Completed	Treatment	Post-Operative Pain	3
3	Completed	Treatment	Postoperative pain	1
3	Not Yet Recruiting	Treatment	Obstetric Pain / Other Complications of Obstetric Anesthesia - Delivered	1
3	Recruiting	Treatment	Lumbar epidural anesthesia therapy	1
4	Active Not Recruiting	Treatment	Driving Performance After Minor Ambulatory Surgery / Minor Surgical Procedures With Monitored Anesthesia Care	1
4	Active Not Recruiting	Treatment	Trigeminal Neuralgia (TN)	1
4	Completed	Not Available	Aortic Aneurysms	1
4	Completed	Basic Science	Anaesthesia therapy	1
4	Completed	Prevention	Aortic Valve Stenosis / Ischaemic Heart Diseases	1
4	Completed	Supportive Care	Pain	1
4	Completed	Supportive Care	Postoperative pain / Prophylaxis against postoperative nausea and vomiting	1
4	Completed	Treatment	Analgesics / Pain, Chronic / Postoperative pain	1
4	Completed	Treatment	Numeric Pain Rating Scale > 5 / 10 / Severe Traumatic Pain	1
4	Completed	Treatment	Pain	3
4	Completed	Treatment	Postoperative pain	2
4	Completed	Treatment	Single Traumatic Limb Injury With Severe Pain (Score > 5/10 on Numerical Pain Scale)	1
4	Enrolling by Invitation	Supportive Care	Postoperative; Dysfunction Following Cardiac Surgery	1
4	Not Yet Recruiting	Prevention	Postoperative Cognitive Dysfunction / Postoperative Delirium	1
4	Not Yet Recruiting	Treatment	Analgesia, Patient-Controlled / Anesthesia; Spinal / Intravenous Drug Delivery Systems / Lumbar epidural anesthesia / Morphine / Surgery, Colorectal	1
4	Not Yet Recruiting	Treatment	Anesthesia; Functional	1
4	Recruiting	Prevention	Coronary Artery Bypass Graft Redo / General Anesthetic Drug Adverse Reaction	1
4	Recruiting	Supportive Care	Pregnancy	1
4	Recruiting	Treatment	Arteriovenous Malformations	1
4	Recruiting	Treatment	Labour Pain	1
4	Recruiting	Treatment	Labour Pain / Lumbar epidural anesthesia therapy / Opioids	1
4	Recruiting	Treatment	Pain, Acute	1
4	Recruiting	Treatment	Patients Ongoing Elective Abdominal Laparoscopy	1
4	Recruiting	Treatment	Postoperative pain	1
4	Terminated	Treatment	Analgesia / Sedation therapy	1
4	Terminated	Treatment	Thoracic Surgery	1
4	Unknown Status	Treatment	Adrenal Suppression / Hemodynamics Instability	1
4	Unknown Status	Treatment	Analgesia, Patient-Controlled / Arthroplasty / Gastric Resection	1
Not Available	Completed	Not Available	Adequate Anesthesia With Unimpaired Motor Strength	1
Not Available	Completed	Diagnostic	Prostate Cancer	1
Not Available	Completed	Other	Loss of Consciousness	1
Not Available	Completed	Prevention	Anaesthesia therapy / Pain	1
Not Available	Completed	Prevention	Kidney Donation/Transplantation	1
Not Available	Completed	Prevention	Prophylaxis against postoperative nausea and vomiting	1
Not Available	Completed	Screening	Knee Surgery With Tourniquet	1
Not Available	Completed	Supportive Care	Epidural Block / Malignant Neoplasm of Esophagus / Oesophagectomy	1
Not Available	Completed	Supportive Care	Instrumental Delivery / Lumbar epidural anesthesia / Maternal Outcome / Neonatal Outcome	1
Not Available	Completed	Supportive Care	Total Knee Arthroplasty (TKA)	1
Not Available	Completed	Treatment	Anaesthesia therapy	1
Not Available	Completed	Treatment	Anesthesia Complications	1
Not Available	Completed	Treatment	Balanced Anesthesia	1
Not Available	Completed	Treatment	Ischaemic Heart Diseases	1
Not Available	Completed	Treatment	Labour Pain	1
Not Available	Completed	Treatment	Neoplasms, Pancreatic	1
Not Available	Completed	Treatment	Pediatric Ventricular Septal Defects	1
Not Available	Completed	Treatment	Post Operative Pain Management	1
Not Available	Not Yet Recruiting	Supportive Care	Cardiovascular Disease (CVD)	1
Not Available	Not Yet Recruiting	Treatment	C.Delivery; Surgery (Previous), Gynecological	1
Not Available	Not Yet Recruiting	Treatment	Liver Diseases / Neoplasms, Hepatic / Secondary Malignant Neoplasm of Liver	1
Not Available	Recruiting	Not Available	Analgesic Quality / Mobility	1
Not Available	Recruiting	Treatment	Labor Analgesia	1
Not Available	Recruiting	Treatment	Labour Pain	1
Not Available	Recruiting	Treatment	Postoperative Complications	1
Not Available	Terminated	Diagnostic	Labour Pain	1
Not Available	Unknown Status	Health Services Research	Pregnancy	1
Not Available	Unknown Status	Supportive Care	Adjunct to general anesthesia therapy	1
Not Available	Unknown Status	Treatment	Haemodynamic Fluctuations During Off-pump CABG	1

Pharmacoeconomics

Manufacturers

Akorn inc
Baxter healthcare corp anesthesia and critical care
Hospira inc
Watson laboratories inc

Packagers

Akorn Inc.
Baxter International Inc.
Generamedix Inc.
Hospira Inc.
Mallinckrodt Inc.
Taylor Pharmaceuticals

Dosage forms

Form	Route	Strength
Liquid	Epidural; Intravenous	50 mcg
Liquid	Intravenous	50 mcg
Injection	Epidural; Intravenous	.05 mg/mL
Injection	Epidural; Intravenous	50 ug/mL
Injection, solution	Epidural; Intravenous	50 ug/mL
Solution	Epidural; Intravenous	50 mcg
Tablet	Sublingual	15 μg

Prices

Unit description	Cost	Unit
Sufentanil citrate powder	18927.0USD	g
Sufenta 50 mcg/ml ampul	5.38USD	ml
Sufentanil 50 mcg/ml ampul	3.92USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	97 °C	PhysProp
water solubility	76 mg/L (at 25 °C)	ROY,SD & FLYNN,GL (1988)
logP	3.95	SANGSTER (1993)
logS	-3.71	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	0.012 mg/mL	ALOGPS
logP	3.4	ALOGPS
logP	3.61	ChemAxon
logS	-4.5	ALOGPS
pKa (Strongest Basic)	8.86	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	32.78 Å²	ChemAxon
Rotatable Bond Count	8	ChemAxon
Refractivity	111.42 m³·mol^-1	ChemAxon
Polarizability	43.85 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9875
Blood Brain Barrier	+	0.9886
Caco-2 permeable	+	0.5201
P-glycoprotein substrate	Substrate	0.6673
P-glycoprotein inhibitor I	Inhibitor	0.8275
P-glycoprotein inhibitor II	Inhibitor	0.8387
Renal organic cation transporter	Non-inhibitor	0.5594
CYP450 2C9 substrate	Non-substrate	0.7923
CYP450 2D6 substrate	Non-substrate	0.9116
CYP450 3A4 substrate	Substrate	0.713
CYP450 1A2 substrate	Non-inhibitor	0.8954
CYP450 2C9 inhibitor	Non-inhibitor	0.7839
CYP450 2D6 inhibitor	Non-inhibitor	0.8416
CYP450 2C19 inhibitor	Non-inhibitor	0.5438
CYP450 3A4 inhibitor	Inhibitor	0.6293
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.6401
Ames test	Non AMES toxic	0.7695
Carcinogenicity	Non-carcinogens	0.8861
Biodegradation	Not ready biodegradable	0.9724
Rat acute toxicity	3.0968 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9793
hERG inhibition (predictor II)	Inhibitor	0.772

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-000i-0009000000-0f9e477eb2153eb20409
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-000i-0096000000-73641c83c08b872641cd
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-06ri-1981000000-b5f4aaab095cc6fc533c
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-03di-1900000000-2fdfd1d5fa6e43fa1604
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-03di-4900000000-bd92c052347dc0822a01

Taxonomy

Description: This compound belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution.
Kingdom: Organic compounds
Super Class: Benzenoids
Class: Benzene and substituted derivatives
Sub Class: Anilides
Direct Parent: Anilides
Alternative Parents: Aralkylamines / Piperidines / Thiophenes / Tertiary carboxylic acid amides / Heteroaromatic compounds / Trialkylamines / Amino acids and derivatives / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents: Anilide / Aralkylamine / Piperidine / Tertiary carboxylic acid amide / Heteroaromatic compound / Thiophene / Amino acid or derivatives / Carboxamide group / Tertiary amine / Tertiary aliphatic amine
show 15 more
Molecular Framework: Aromatic heteromonocyclic compounds
External Descriptors: piperidines, thiophenes, ether, anilide (CHEBI:9316)

Targets

Details1. Mu-type opioid receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Agonist

General Function: Voltage-gated calcium channel activity
Specific Function: Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name: OPRM1
Uniprot ID: P35372
Uniprot Name: Mu-type opioid receptor
Molecular Weight: 44778.855 Da

References

Hurle MA: Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity. J Neurochem. 2001 Apr;77(2):486-92. [PubMed:11299311]
Levron JC: [Pharmacokinetics and pharmacodynamics of morphinomimetics in the central nervous system]. Agressologie. 1991;32(6-7):318-20. [PubMed:1688220]
Ilien B, Galzi JL, Mejean A, Goeldner M, Hirth C: A mu-opioid receptor-filter assay. Rapid estimation of binding affinity of ligands and reversibility of long-lasting ligand-receptor complexes. Biochem Pharmacol. 1988 Oct 15;37(20):3843-51. [PubMed:2847746]
Colpaert FC, Leysen JE, Michiels M, van den Hoogen RH: Epidural and intravenous sufentanil in the rat: analgesia, opiate receptor binding, and drug concentrations in plasma and brain. Anesthesiology. 1986 Jul;65(1):41-9. [PubMed:3014923]
Leysen JE, Gommeren W: In vitro binding properties of 3H-sufentanil, a superior ligand for the mu-opiate receptor. Arch Int Pharmacodyn Ther. 1982 Dec;260(2):287-9. [PubMed:6131653]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Property	Measurement	pH	Temperature (°C)	References
Ki (nM)	50	N/A	N/A	8114680

Details2. Delta-type opioid receptor

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Agonist

General Function: Opioid receptor activity
Specific Function: G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name: OPRD1
Uniprot ID: P41143
Uniprot Name: Delta-type opioid receptor
Molecular Weight: 40368.235 Da

References

Freye E, Latasch L, Portoghese PS: The delta receptor is involved in sufentanil-induced respiratory depression--opioid subreceptors mediate different effects. Eur J Anaesthesiol. 1992 Nov;9(6):457-62. [PubMed:1330549]
Zhu J, Xue JC, Law PY, Claude PA, Luo LY, Yin J, Chen C, Liu-Chen LY: The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor. FEBS Lett. 1996 Apr 15;384(2):198-202. [PubMed:8612823]

Property	Measurement	pH	Temperature (°C)	References
Ki (nM)	75	N/A	N/A	8114680

Details3. Kappa-type opioid receptor

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Other

General Function: Opioid receptor activity
Specific Function: G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name: OPRK1
Uniprot ID: P41145
Uniprot Name: Kappa-type opioid receptor
Molecular Weight: 42644.665 Da

References

Zhu J, Xue JC, Law PY, Claude PA, Luo LY, Yin J, Chen C, Liu-Chen LY: The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor. FEBS Lett. 1996 Apr 15;384(2):198-202. [PubMed:8612823]
Chang HM, Berde CB, Holz GG 4th, Steward GF, Kream RM: Sufentanil, morphine, met-enkephalin, and kappa-agonist (U-50,488H) inhibit substance P release from primary sensory neurons: a model for presynaptic spinal opioid actions. Anesthesiology. 1989 Apr;70(4):672-7. [PubMed:2467589]

Enzymes

Details1. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:24

Sufentanil

Identification

Structure for DB00708 (Sufentanil)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

References

References

Enzymes

References